Back to the future of targeting leukotriene B₄ mediated inflammation

Semin Immunol. 2017 Oct:33:1-2. doi: 10.1016/j.smim.2017.09.010. Epub 2017 Oct 4.

Author

Bodduluri Haribabu¹

Affiliation

¹ James Graham Brown Cancer Center, University of Louisville Health Sciences Center, Louisville, KY 40202, USA; Department of Microbiology and Immunology, University of Louisville Health Sciences Center, Louisville, KY 40202, USA. Electronic address: H0bodd01@louisville.edu.

PMID: 28988622
DOI: 10.1016/j.smim.2017.09.010

No abstract available

Publication types

Editorial

MeSH terms

5-Lipoxygenase-Activating Proteins / metabolism
Acetates / therapeutic use
Animals
Asthma / drug therapy*
Cell Movement
Chemokines / metabolism
Cyclopropanes
Epoxide Hydrolases / metabolism
Humans
Inflammation / immunology*
Inflammation / therapy
Leukotriene B4 / metabolism*
Lipid Metabolism
Molecular Targeted Therapy
Neutrophil Activation
Neutrophils / immunology*
Quinolines / therapeutic use
Sulfides
T-Lymphocytes / immunology*

Substances

5-Lipoxygenase-Activating Proteins
ALOX5AP protein, human
Acetates
Chemokines
Cyclopropanes
Quinolines
Sulfides
Leukotriene B4
Epoxide Hydrolases
montelukast
leukotriene A4 hydrolase